Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 14/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20519426 | 0.81 | BAZ2B (0.47) | PHGDHMAPTKDM4EMEN1KMT2A | |
| SCHEMBL26843192 | 0.79 | MEN1 (0.44) | PHGDHMAPTKDM4EMEN1KMT2A | |
| SCHEMBL22290279 | 0.77 | CA12 (0.45) | MAPTKDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL31493114 | 0.74 | KDM4E (0.39) | PHGDHMAPTKDM4EMEN1KMT2A | |
| SCHEMBL19253450 | 0.74 | GRN (0.56) | PHGDHKDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL24484133 | 0.73 | KDM4E (0.38) | PHGDHMAPTKDM4EMEN1KMT2A | |
| SCHEMBL27907432 | 0.73 | MEN1 (0.41) | PHGDHMAPTKDM4EMEN1KMT2A | |
| SCHEMBL29148601 | 0.73 | GRN (0.55) | PHGDHMAPTKDM4EMEN1KMT2A | |
| SCHEMBL22303448 | 0.72 | MAPT (0.50) | PHGDHMAPTKDM4EL3MBTL1 | |
| SCHEMBL26036174 | 0.72 | MEN1 (0.38) | MAPTKDM4EMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | PHGDH 1316/4885MAPT 718/4885KDM4E 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.